Home › NDC Lookup › RxCUI directory › RxCUI 2680784

Sprinkle valbenazine 80 MG Oral Capsule [Ingrezza] — RxCUI 2680784

Name: Sprinkle valbenazine 80 MG Oral Capsule [Ingrezza] (RxCUI 2680784)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2680784 Semantic branded drug · SBD ● Current RxNorm concept 8 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2680784

Official nameSprinkle valbenazine 80 MG Oral Capsule [Ingrezza]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asIngrezza Sprinkle 80 MG Oral Capsule

FDA products mapped8

Package NDCs mapped8

Reported Medicaid activity (SDUD)83,640 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Valbenazine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Valbenazine is designed to reduce the uncontrolled, involuntary movements that can be really disruptive to daily life. If you have tardive dyskinesia — those repetitive facial or b...
What exactly is this medication supposed to do for me?
Yes, drowsiness is the most commonly reported side effect — so this is worth planning for. Some people find it quite manageable, while others feel it more strongly, especially when...
Yes, and this is really important. Valbenazine carries a serious warning specifically for people with Huntington's disease: it can increase the risk of depression and suicidal thou...

📖 Read our full Valbenazine guide →

🕸️ Concept Web — How Sprinkle valbenazine 80 MG Oral Capsule [Ingrezz... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Sprinkle valbenazine 80 MG Oral Capsule [Ingrezza] RxCUI 2680784 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Valbenazine 1918219 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Ingrezza 1918225 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Valbenazine Oral Capsule 1918223 SCDF
- Valbenazine Oral Product 1918221 SCDG
- Valbenazine Pill 1918222 SCDG
- Valbenazine Oral Capsule [Ingrezza] 1918227 SBDF
- Ingrezza Oral Product 1918228 SBDG
- Ingrezza Pill 1918229 SBDG
- Oral Capsule 316965 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Sprinkle valbenazine 80 MG Oral Capsule 2680783 SCD
- Valbenazine 80 MG 1986328 SCDC
- Valbenazine 80 MG [Ingrezza] 1986330 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Sprinkle valbenazine 80 MG Oral Capsule SCD · 2680783
Valbenazine 80 MG SCDC · 1986328
Valbenazine Oral Capsule SCDF · 1918223
Valbenazine Oral Product SCDG · 1918221
Valbenazine Pill SCDG · 1918222

Brand-Name Concepts

Valbenazine 80 MG [Ingrezza] SBDC · 1986330
Valbenazine Oral Capsule [Ingrezza] SBDF · 1918227
Ingrezza Oral Product SBDG · 1918228
Ingrezza Pill SBDG · 1918229
Ingrezza BN · 1918225

📦 FDA Products & Package NDCs

8 products · 8 package NDCs

8 package NDCs map to RxCUI 2680784 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
70370-1060-01	30 CAPSULE in 1 BOTTLE (70370-1060-1)	INGREZZA	Neurocrine Biosciences, Inc.	2021-04-23
70370-1080-01	30 CAPSULE in 1 BOTTLE (70370-1080-1)	INGREZZA	Neurocrine Biosciences, Inc.	2017-10-04
70370-2040-01	30 CAPSULE in 1 BOTTLE (70370-2040-1)	INGREZZA	Neurocrine Biosciences, Inc.	2018-12-14
70370-2046-01	1 BLISTER PACK in 1 CARTON (70370-2046-1) / 1 KIT in 1 BLIS...	INGREZZA	Neurocrine Biosciences, Inc.	2023-08-18
70370-2048-06	1 BLISTER PACK in 1 CARTON (70370-2048-6) / 1 KIT in 1 BLIS...	INGREZZA	Neurocrine Biosciences, Inc.	2018-12-14
70370-4040-01	30 CAPSULE in 1 BOTTLE (70370-4040-1)	INGREZZA Sprinkle	Neurocrine Biosciences, Inc.	2024-04-30
70370-4060-01	30 CAPSULE in 1 BOTTLE (70370-4060-1)	INGREZZA Sprinkle	Neurocrine Biosciences, Inc.	2024-04-30
70370-4080-01	30 CAPSULE in 1 BOTTLE (70370-4080-1)	INGREZZA Sprinkle	Neurocrine Biosciences, Inc.	2024-04-30

Observed labelers: Neurocrine Biosciences, Inc. (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.